Janus Henderson Group PLC Purchases Shares of 648,118 Celcuity Inc. (NASDAQ:CELC)

Janus Henderson Group PLC bought a new stake in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 648,118 shares of the company's stock, valued at approximately $8,468,000. Janus Henderson Group PLC owned approximately 1.75% of Celcuity at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Baker BROS. Advisors LP increased its holdings in Celcuity by 42.9% during the 4th quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company's stock valued at $35,062,000 after acquiring an additional 803,575 shares in the last quarter. Vanguard Group Inc. increased its holdings in Celcuity by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company's stock valued at $21,624,000 after acquiring an additional 24,429 shares in the last quarter. Geode Capital Management LLC increased its holdings in Celcuity by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 692,372 shares of the company's stock valued at $9,065,000 after acquiring an additional 62,003 shares in the last quarter. Artisan Partners Limited Partnership increased its holdings in Celcuity by 18.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 491,507 shares of the company's stock valued at $6,434,000 after acquiring an additional 75,830 shares in the last quarter. Finally, Captrust Financial Advisors boosted its stake in shares of Celcuity by 1.4% during the 4th quarter. Captrust Financial Advisors now owns 468,096 shares of the company's stock worth $6,127,000 after purchasing an additional 6,302 shares during the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CELC has been the topic of several analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price target on shares of Celcuity in a research note on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of Celcuity in a research note on Monday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $30.80.

Celcuity Trading Down 0.5%

Shares of CELC traded down $0.05 during mid-day trading on Wednesday, hitting $10.60. The company had a trading volume of 124,620 shares, compared to its average volume of 297,726. The business's 50-day simple moving average is $10.16 and its 200-day simple moving average is $11.60. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. Celcuity Inc. has a 1-year low of $7.58 and a 1-year high of $19.77. The stock has a market cap of $401.09 million, a PE ratio of -4.06 and a beta of 0.56.

Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.09. Sell-side analysts forecast that Celcuity Inc. will post -2.62 earnings per share for the current year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.